More about

Ovarian Cancer

News
June 10, 2022
2 min read
Save

Relacorilant regimen prolongs survival in recurrent platinum-resistant ovarian cancer

Relacorilant regimen prolongs survival in recurrent platinum-resistant ovarian cancer

CHICAGO — Intermittent relacorilant plus nab-paclitaxel demonstrated an OS benefit among women with recurrent platinum-resistant/refractory ovarian cancer compared with nab-paclitaxel alone.

News
June 06, 2022
3 min read
Save

Rucaparib shows efficacy as first-line maintenance therapy in ovarian cancer

Rucaparib shows efficacy as first-line maintenance therapy in ovarian cancer

CHICAGO — Rucaparib monotherapy significantly prolonged PFS compared with placebo in the first-line maintenance setting among women with advanced ovarian cancer, regardless of BRCA mutation and homologous recombination deficiency status.

News
May 08, 2022
2 min watch
Save

VIDEO: O-RADS ultrasound may prevent unnecessary ovarian cancer surgery

VIDEO: O-RADS ultrasound may prevent unnecessary ovarian cancer surgery

SAN DIEGO — In this video, Rochelle F. Andreotti, MD, a professor of clinical radiology, radiological sciences and OB/GYN at Vanderbilt University Medical Center, recaps her endowed lecture on adnexal mass evaluation.

News
May 02, 2022
1 min read
Save

FDA grants fast track designation to ofranergene obadenovec for advanced ovarian cancer

FDA grants fast track designation to ofranergene obadenovec for advanced ovarian cancer

The FDA granted fast track designation to ofranergene obadenovec in combination with paclitaxel for treatment of platinum-resistant ovarian cancer.

News
April 22, 2022
1 min read
Save

Break Through Cancer awards $50M to fund ‘radical collaboration’ in cancer research

Break Through Cancer awards $50M to fund ‘radical collaboration’ in cancer research

Break Through Cancer will award $50 million in grants designed to maximize interdisciplinary collaboration among researchers at five top cancer centers.

News
April 12, 2022
3 min read
Save

CAR-T with, without mRNA vaccine shows promise for solid tumors

CAR-T with, without mRNA vaccine shows promise for solid tumors

Early data from a phase 1 trial showed encouraging clinical activity for an investigational chimeric antigen receptor T-cell therapy alone or in combination with an amplifying mRNA vaccine for patients with solid tumors.

News
March 31, 2022
2 min read
Save

Rubraca extends PFS as maintenance therapy in ovarian cancer, topline data show

Rubraca extends PFS as maintenance therapy in ovarian cancer, topline data show

Rucaparib monotherapy significantly extended PFS compared with placebo as first-line maintenance treatment for women with ovarian cancer, according to topline data from the randomized phase 3 ATHENA-MONO trial.

News
March 24, 2022
2 min read
Save

MAPK mutations linked to longer survival in ovarian cancer subset

MAPK mutations linked to longer survival in ovarian cancer subset

Women with mitogen-activated protein kinase-mutated low-grade serous ovarian/peritoneal carcinoma experienced significantly longer PFS and OS compared with women without these mutations, according to study results.

News
March 23, 2022
2 min read
Save

Mirvetuximab soravtansine shows antitumor activity in platinum resistant ovarian cancer

Mirvetuximab soravtansine shows antitumor activity in platinum resistant ovarian cancer

Mirvetuximab soravtansine demonstrated efficacy and tolerability in patients with platinum resistant ovarian cancer, according to phase 3 clinical data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

News
March 22, 2022
3 min read
Save

Mirvetuximab soravtansine shows durable efficacy in ovarian cancer subset

Mirvetuximab soravtansine shows durable efficacy in ovarian cancer subset

Folate receptor alpha expression predicted benefit from mirvetuximab soravtansine in platinum-resistant high-grade serous epithelial ovarian, primary peritoneal or fallopian tube cancers, according to a results of the phase 3 SORAYA study.

View more